Associated tags: Inflammation, Glaucoma, Dry eye syndrome, Ocular hypertension, Fabry disease, VBI, Patient, Therapy, Pharmaceutical industry, FDA, Phase, RNA, Pharmacokinetics, Safety, URAT1, Drug development, Facet joint arthrosis, GCS, SUA, Strong, American College, Research
Fabry disease,
RMB,
PD,
Drug development,
Strong,
Ohio State University,
RNA,
Insight Partners,
Pharmacology,
American College,
Radiopharmaceutical,
VBI,
Willebrand,
RTW,
Pattern hair loss,
GMP,
Stroke,
Good manufacturing practice,
Therapy,
Skin,
GCS,
Atopic dermatitis,
Safety,
Pharmacokinetics,
Von Willebrand factor,
Investment,
AstraZeneca,
Innovation,
Groundbreaking,
Patient,
ARCH Venture Partners,
Pharmaceutical industry NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.
Key Points:
- This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
- Recently, Viva Biotech's portfolio companies have new updates.
- NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
- Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.
JAK1,
NMPA,
Patient,
American College of Rheumatology,
Bayer,
SUA,
Neoplasm,
Cataract,
Therapy,
URAT1,
MBA,
Cancer,
Health care,
Inflammation,
Fabry disease,
Safety,
Toxicity,
IND,
SHP2,
USD,
Strong,
Letter,
Woman,
EA Phenomic,
Pharmacokinetics,
VBI,
HER2,
MPM,
Antibody,
GCS,
GEJ,
Boehringer,
Research,
Plasma,
Boehringer Ingelheim,
Clinical trial,
Investment,
MaRS Discovery District,
FDA,
American College,
Phase II,
Clostridial necrotizing enteritis,
Selective,
MPH,
ACR,
EGFR,
Pharmaceutical industry,
Astellas Pharma,
Phase,
Deka,
Facet joint arthrosis TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--On Nov. 29th, Phenomic AI ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales.
Key Points:
- HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
- This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
- Recently, Viva's portfolio companies have new updates.
- Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones.
Dai,
FALCON,
Head,
Acquisition,
Patient,
Fabry disease,
SUA,
Tissue,
Pharma,
Gout,
Therapy,
Heart failure,
CSO,
GABAA receptor negative allosteric modulator,
Research,
NAM,
VBI,
Small RNA,
Medicine,
Liver,
Growth,
CIO,
Listeria monocytogenes non-coding RNA,
Phase,
FDA,
URAT1,
G protein-coupled receptor,
SRT,
PAR2,
DSM-IV codes,
Gq alpha subunit,
Glaucoma,
Ocular hypertension,
SAN,
Mercury (element),
Allosteric regulation,
IOP,
Flare,
Central nervous system,
Drug development,
Quality of life,
Facet joint arthrosis,
RNA,
Novartis,
Cardiology,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Food,
Pharmaceutical industry,
Fine chemical,
Riparian zone,
Domain,
Pfizer WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.
Key Points:
- WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases.
- Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.
- In exchange for exclusive rights to a Riparian preclinical program, Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics.
- DTx Pharma utilizes its groundbreaking FALCON™ platform, a conjugated oligonucleotide technology using fatty acid ligands, to tackle the delivery challenges of oligonucleotide therapies.
